An Open Label Pragmatic Feasibility Study on a Resilience Focused Community of Practice Program With Psilocybin-assisted Therapy (PaT) for End-of-Life Patients.
试验速览
- 阶段
- 早期 1 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 64
- 主要终点
- Primary Outcome 3: Safety Monitoring: Biomedical measures - Pregnancy testing
研究概览
简要总结
The purpose of the study is to understand the feasibility of a resilience focused community of practice program that includes psilocybin-assisted therapy for End-of-Life Distress. The community of practice refers to a research informed group therapy process that runs over a 10-week period of time and includes one group administered psilocybin-assisted therapy session.
Target population: The treatment team will treat a total of 64 patients who have:
- a terminal diagnosis (experiencing end of life distress),
- AND who are eligible for the RTT + Psilocybin-assisted Therapy Treatment program through the RTT Society.
详细描述
Treatment will take place at the Snuneymuxw Traditional Medicines Clinic, 1984 Woobank Rd, Nanaimo, B.C.Research data will be coordinated and held through RedCap, hosted by Island Health.
Data collection centres on 1) understanding the feasibility; 2) collecting safety data; 3) exploring the mental health impacts of a community of practice as the vessel for psilocybin-assisted therapy for those with end-of-life distress.
There is a mixed method approach for data collection, including:
- Collect attendance
- Biomedical measures taken during psilocybin sessions (blood pressure, pulse, medications to manage side effects).
- Quantitative Health and Wellness Questionnaires of participants before, within, immediately after, and six months after completion.
- Qualitative Surveys and Exit Interviews.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 19 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- •Treatment in a clinical trial where psilocybin therapy would disqualify them from their primary treatment trial.
- •If female is:a) pregnant (positive pregnancy test),b) nursing,
- •Currently taking on a regular (e.g., daily) basis: >investigational agents, >medications that are MAO inhibitors >UDG modulators, and inhibitors of UGT1A9 and 1A10, aldehyde or alcohol dehydrogenase inhibitors, SSRI's, SNRI's.
- •Patients are given the option to wean themselves off their medications prior to the psilocybin to be included in the trial. Patients taking MAO-A inhibitors (especially the irreversible inhibitors) will require a minimum 2-week washout period. The possible concern over serotonin syndrome with these agents is not well documented in the literature, however the long interval before MAO is replenished may warrant a cautious approach based on the patient's risk factors and warrants oversight from the MRP (Most Responsible Physician)
- •Patientstaking MAO-B inhibitors should be assessed on a case by case basis as there is a potential for a heightened response and warrants oversight from the MRP.
- •Patients with known sensitivities to psilocybin and or its metabolites or have had significant adverse events after prior psilocybin or other psychedelic use.
- •Active uncontrolled epilepsy.
- •Uncontrolled cardiovascular conditions: uncontrolled hypertension, uncontrolled angina, a clinically significant ECG abnormality (e.g. QT prolongation).
- •Uncontrolled vascular disease (such as TIA in the last 3-6 months, stroke with loss in mental status, peripheral or pulmonary vascular disease with active claudication).
- •Unstable Insulin-dependent diabetes;
- •Conditions requiring special medical consideration:
- •Cancer has central nervous system involvement.
- •Paraneoplastic syndrome or a tumor with ectopic hormone production which may place the patient at risk for hypercalcemia, Cushing's syndrome, or SIADH secretion.
- •Psychiatric Exclusion Criteria:
- •Severity of depression or anxiety symptoms warranting immediate emergent treatment with antidepressant or daily anxiolytic medication as these patients would require immediate referral to community psychiatry.
- •Current or past history of meeting DSM-5 criteria for:
- •(the following diagnoses must have been confirmed by a qualified psychiatrist or psychologist):
- •Schizophrenia;
- •Psychotic Disorder (unless substance-induced or due to a medical condition);○ Borderline Personality Disorder;
- •Bipolar I Disorder;
- •Bipolar II Disorder;
- •Other psychiatric conditions judged to be incompatible with establishment of rapport or safe exposure to psilocybin.
- •Borderline Personality Disorder, Bipolar I Disorder and Bipolar II Disorder may be considered after a psychiatric consult.
- •Bipolar I would require more in-depth investigation in relation to the history of manic episodes.
- •Meet DSM-5 criteria for Dissociative Disorder
- •Concurrent use of illicit drugs causing ongoing intoxication
- •Unstable housing conditions (homelessness)
- •First degree relatives meet DSM-5 criteria for Bipolar Disorder or Schizophrenia
研究组 & 干预措施
Single arm
Group administered Psilocybin-assisted therapy
干预措施: Psilocybin-assisted therapy within a community of practice model (group administered) (Drug)
结局指标
主要结局
Primary Outcome 3: Safety Monitoring: Biomedical measures - Pregnancy testing
时间窗: Immediately prior to treatment intervention session (Week 5)
A urine pregnancy test measuring beta-human chorionic gonadotropin (B-hCG) will be conducted on the pre-treatment targeted physical exam visit to ensure the participant is not pregnant. If the pregnancy test is positive, the participant will be unable to participate in the treatment intervention at Week 5 but will be invited to remain in group therapy interventions sessions (Weeks 1-10).
Primary Outcome 3: Safety Monitoring: Biomedical measures - Blood Pressure
时间窗: Treatment intervention session (Week 5)
Vitals signs, including blood pressure (millimeters of mercury/mmHg) will be measured before, during, and after the treatment intervention session.
Primary Outcome 1: Treatment Intervention Phase - Safety Monitoring: Adverse events (AEs), serious adverse events (SAEs) and treatment emergent adverse events (TEAEs)
时间窗: Treatment intervention period: Weeks 1 through 10
Safety in the trial will be evaluated by monitoring AEs, SAEs, and TEAEs over the 10-week intervention period. Adverse events will be defined and documented according to the adverse reporting procedures and be collected via self-report, report from others, or chart abstraction.
Primary Outcome 3: Safety Monitoring: Biomedical measures - Heart Rate
时间窗: Treatment intervention session (Week 5)
Vitals signs, including heart rate (beats per minute/BPM) will be measured before, during, and after the treatment intervention session.
Primary Outcome 2: Follow-up to Treatment Phase - Safety Monitoring: Adverse events (AEs), serious adverse events (SAEs) and treatment emergent adverse events (TEAEs)
时间窗: Follow-up period: Weeks 10 through 14
Safety in the trial will be evaluated by monitoring AEs, SAEs, and TEAEs during the 30-day treatment intervention follow-up phase. Adverse events will be defined and documented according to the adverse reporting procedures and be collected via self-report, report from others, or chart abstraction.
次要结局
- Feasibility Outcome 1: Attendance during study intervention.(Weeks 1-10)
- Feasibility Outcome 2: Post-treatment intervention Qualitative Survey(End of treatment intervention period: Week 10)